NeoVentures Biotechnology Europe Partners with Ombion Biomarker discovery has been and remains a key to advancing treatments in healthcare. The majority of the science in this area has relied on antibody production with the introduction…
NeoVentures Biotechnology Europe has joined NVIDIA Inception, a program designed to help startups evolve faster through cutting-edge technology and access to the latest technical resources from NVIDIA. At NVB Europe, we’ve developed the Aptamarker Platform,…
The Institut de Recherche pour le Développement, Délégation Régionale Occitanie (IRD-Montpellier), and NeoVentures Biotechnology Europe (NVBE) are proud to announce a strategic partnership to co-develop the NVBE Aptamarker platform for single-cell proteomics. The Institut de…
NeoNeuro, announced today that it has received an investment from the Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator, an initiative that aims to fast-track the development of novel biomarkers for the early detection of Alzheimer’s disease and…
NeoNeuro SAS has entered into a collaboration under the leadership of Professor Harald Hampel to work with the INSIGHT cohort for the application of the Aptamarker platform to pre-AD samples. The INSIGHT cohort is an innovative…
NeoNeuro SAS is pleased to announce a collaboration with the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) group. The collaboration is focused on exploring the potential of an innovative diagnostic platform developed…
